A joint study on real-world evidence by Verantos and Amgen was published in the Journal of American Medical Informatics Association, the companies announced Wednesday, Sept. 18.
The study’s authors, according to a press release, puts forth a framework for achieving the “high standard needed for advanced regulatory grade evidence.”
“This highlights the importance of routinely measuring accuracy, including sensitivity and specificity, in EHR-based studies intended for regulatory use,” Verantos Founder and CEO Dan Riskin said in a statement. “These are the types of findings that should generate important discussion in the healthcare community as we determine what regulatory-grade RWE means.”
To read the full press release, click here.